Phakic intraocular lenses: an update and review for the treatment of myopia and myopic astigmatism in the United States

Abstract

Purpose of reviewTo review all phakic intraocular lenses (pIOLs) available in the United States for the correction of myopia or myopic astigmatism and offer a clinical approach to their proper use, postoperative follow-up, and analysis of visual and adverse outcomes. Recent findingsIn March 2022, the FDA approved the EVO/EVOþ Visian ICL for widespread use, adding this lens to the two others available (Verisyse, Visian ICL). Cataract formation, endothelial cell loss (ECL) and surgical reintervention remain the most common adverse events. There are discrepancies between studies on ECL following implantation with pIOLs, although trends can be deduced with meta-analysis. Posterior Chamber-pIOLs (PC-pIOLs), especially the EVO/EVOþ, have an overall lower mean adverse effect and subjective patient symptom profile when compared to Iris Fixated-pIOLS (IF-pIOLs). Advancements in PC-pIOL sizing have provided a noticeable difference in visual and safety outcomes.

Clinical decision support system based on deep learning for evaluating implantable collamer lens size and vault after implantable collamer lens surgery: a retrospective study

“…Numerous scholars have conducted research on the selection of ICL size 3 4. Shen et al 5 show that the postoperative ICL vault (the vertical distance from the posterior surface of the ICL to the anterior surface of the lens) is strongly correlated with the ICL size.…”

“…Numerous scholars have conducted research on the selection of ICL size. 3 4 Shen et al 5 show that the postoperative ICL vault (the vertical distance from the posterior surface of the ICL to the anterior surface of the lens) is strongly correlated with the ICL size. Besides, Kim et al 6 establish a new ICL size calculation method and a predictive model for postoperative vault, and demonstrate that ICL size plays an important role in preventing postoperative complications.…”